
LAVA Therapeutics NV
NASDAQ:LVTX

LAVA Therapeutics NV
Other
LAVA Therapeutics NV
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
LAVA Therapeutics NV
NASDAQ:LVTX
|
Other
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Pharming Group NV
AEX:PHARM
|
Other
-$5.6m
|
CAGR 3-Years
43%
|
CAGR 5-Years
27%
|
CAGR 10-Years
-23%
|
|
![]() |
ProQR Therapeutics NV
NASDAQ:PRQR
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Uniqure NV
NASDAQ:QURE
|
Other
-$8.6m
|
CAGR 3-Years
-87%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
argenx SE
XBRU:ARGX
|
Other
-$22m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Merus NV
NASDAQ:MRUS
|
Other
-$325k
|
CAGR 3-Years
-4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
LAVA Therapeutics NV
Glance View
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

See Also
What is LAVA Therapeutics NV's Other?
Other
0
USD
Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Other amounts to 0 USD.